| (USD) | Dec 2023 | Q/Q |
|---|---|---|
| Revenue | 81.3MM | - |
| Operating Income | -42.1MM | -80% |
| Operating Expenses | 120MM | -44% |
| Net Income | -32.7MM | -84% |
| R&D | 64.3MM | -37% |
| G&A | 55.1MM | -29% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Data from a mid-stage study show that Sage's (SAGE) experimental oral drug failed to show a statistically significant difference in treating patients with Parkinson's disease compared with a placebo.
Sage Therapeutics (SAGE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Sage Therapeutics said Wednesday its Parkinson's treatment failed in a midstage study, and Sage stock collapsed to a record low.
Wednesday, Sage Therapeutics Inc (NASDAQ:SAGE) announced topline results from the PRECEDENT Phase 2 study of dalzanemdor (SAGE-718) in people with mild cognitive impairment in Parkinson’s Disease. The PRECEDENT Study did not meet its primary endpoint of demonstrating a statistically significant difference from baseline in participants treated with once-daily dalzanemdor versus placebo on the Wechsler Adult Intelligence Scale Fourth Edition-IV (WAIS-IV) Coding Test score at Day 42. WAIS-IV is the
Following negative results, the company doesn’t plan to further test SAGE-718 in Parkinson’s. Other studies in Huntington’s and Alzheimer’s remain ongoing.
CAMBRIDGE, Mass., April 17, 2024--Sage Therapeutics, Inc. (Nasdaq: SAGE) announced today topline results from PRECEDENT, a double-blind, placebo-controlled Phase 2 study of the investigational oral medicine dalzanemdor (SAGE-718) in people with mild cognitive impairment (MCI) in Parkinson’s Disease (PD). The PRECEDENT Study did not meet its primary endpoint of demonstrating statistically significant difference from baseline in participants treated with once-daily dalzanemdor versus placebo on th
In this piece, we will take a look at the 12 best all time low stocks to invest in. If you want to skip our overview of the latest stock market news and what might happen later this year, then you can skip ahead and take a look at the 5 Best All-Time Stocks To […]
CAMBRIDGE, Mass., April 11, 2024--Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today announced that it will host a live webcast on Thursday, April 25, 2024 at 8:00 a.m. ET to review first quarter 2024 financial results and discuss recent business updates.
In this article, we will take a detailed look at the 12 Best Depressed Stocks To Buy in 2024. For a quick overview of the 5 such stocks, read our article 5 Best Depressed Stocks To Buy in 2024. JPMorgan Chief Jamie Dimon, in his latest letter to shareholders, has warned that the real odds of soft landing a quite […]
The first medicine approved for PPD, Sage’s Zulresso, never gained traction. The company is in the midst of launching its second, but long-standing challenges could slow uptake.